Anti-PD-L1 antibodies and diagnostic uses thereof
AssigneeVentana Medical Systems, Inc.
InventorsMarcin Kowanetz, Hartmut Koeppen, Zachary Boyd, Zhiming Liao, Yifei Zhu, Bharathi Vennapusa, Patrick C. Roche
Life of this patent
Estimating the term…
Abstract
The invention provides programmed death-ligand 1 (PD-L1) antibodies and methods of using the same.
Claims20
A method of detecting the presence or expression level of PD-L1 in a biological sample from a subject comprising contacting the biological sample with an antibody that specifically binds PD-L1 and detecting the presence of the bound antibody, wherein the antibody comprises a heavy chain variable domain (VH) sequence of SEQ ID NO:
- 16 and a light chain variable domain (VL) sequence of SEQ ID NO:
- 17.
A method of detecting the presence or expression level of PD-L1 in a tissue sample from a human subject comprising contacting the tissue sample with an antibody that specifically binds PD-L1 and detecting the presence of the bound antibody, wherein:
- (i) the antibody is a rabbit monoclonal antibody comprising a heavy chain variable domain (VH) sequence of SEQ g ID NO:
- 16 and a light chain variable domain (VL) sequence of SEQ ID NO:
- 17;
- (ii) the expression level of PD-L1 is detected in tumor cells, tumor-infiltrating immune cells, or combinations thereof;
- (iii) the detecting is by immunohistochemistry (INC);
- and
- (iv) the tissue sample comprises formalin-fixed and paraffin-embedded (FFPE) tissue.
Dependencies are inferred from the claim text.